← board
IMRN
distress 4/10 · elevated risk$1.13+0%today-52% from 52w high
Revenue
pre-revenue
Liquidity
$10M
Runway
—
Shares 1y
+64%
Price & events
+13.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.4%
1D
+0.4%
1W
+2.2%
1M
+28.8%
3M
+15.3%
6M
-35.2%
1Y
-56.0%
2Y
-76.6%
5Y
-82.9%
All
Overview
- Market Cap
- $265.47M
- Volume
- 3.92K
- 52 Week Range
- $0.70 – $2.35
- Total Shares
- 233.96M
- Float Shares
- 7.99M
- Short %
- 1.44%
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 1.05%
- RVOL
- 0.08x
- Beta
- 0.50
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2024-09-26Litchfield HillsBuy
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.